In recent years, cannabis use by people suffering from PTSD, as a means of alleviating their symptoms, has increased. Nonetheless, scant research has examined the lived experience of women who use cannabis to cope with PTSD. Eight semi-structured interviews with Israeli women who use cannabis to cope with PTSD were analyzed using interpretative phenomenological analysis (IPA). The results of this research highlight the utility of cannabis for women coping with symptoms of PTSD, and the advantages of cannabis over other medications. Nevertheless, the main challenge with cannabis use in the context of PTSD is the feeling of detachment that it engenders. This feeling of detachment helps women to manage symptoms when they become unbearable but can also reduce their ability to be fully present in their relationships and everyday life, and increase feelings of self-alienation and helplessness.
AgoffC.FondevilaG.SandbergS. (2021). Cultural stigmatization and police corruption: Cannabis, gender, and legalization in Mexico. Drugs: Education, Prevention and Policy, 1–9. https://doi.org/10.1080/09687637.2021.2004089
2.
AtakanZ. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241–254. https://doi.org/10.1177/2045125312457586
3.
Author (2005).
4.
Author (2019).
5.
AviramJ.LewitusG. M.VysotskiY.BermanP.ShapiraA.ProcacciaS.MeiriD. (2022). Sex differences in medical cannabis-related adverse effects. Pain, 163(5), 975. https://doi.org/10.1097/j.pain.0000000000002463
6.
Bedard-GilliganM.LehingerE.Cornell-MaierS.HollowayA.ZoellnerL. (2022). Effects of cannabis on PTSD recovery: Review of the literature and clinical insights. Current Addiction Reports, 9, 203–216. DOI:10.1007/s40429-022-00414-x
7.
BodenM. T.BabsonK. A.VujanovicA. A.ShortN. A.Bonn‐MillerM. O. (2013). Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. American Journal on Addictions, 22(3), 277–284. https://doi.org/10.1111/j.1521-0391.2012.12018.x
8.
Bonn-MillerM. O.SisleyS.RiggsP.Yazar-KlosinskiB.WangJ. B.LoflinM. J.DoblinR. (2021). The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PloS One, 16(3), e0246990. https://doi.org/10.1371/journal.pone.0246990
9.
BraunI.TulskyJ. (2018). Reconciling the discrepancies in medicine's relationship to medical marijuana. Annals of Internal Medicine, 169(9):646–647. https://doi.org/10.7326/M18-1883
10.
BryantR. A. (2019). Post‐traumatic stress disorder: A state‐of‐the‐art review of evidence and challenges. World Psychiatry, 18(3), 259–269. https://doi.org/10.1002/wps.20656
11.
BucknerJ. D.ZvolenskyM. J.SchmidtN. B. (2012). Cannabis-related impairment and social anxiety: The roles of gender and cannabis use motives. Addictive Behaviors, 37(11), 1294–1297. https://doi.org/10.1016/j.addbeh.2012.06.013
12.
CampbellN. D.HerzbergD. (2017). Gender and critical drug studies: An introduction and an invitation. Contemporary Drug Problems, 44(4), 251–264.
13.
CooperZ. D.CraftR. M. (2018). Sex-dependent effects of cannabis and cannabinoids: A translational perspective. Neuropsychopharmacology, 43(1), 34–51. https://doi.org/10.1038/npp.2017.140
14.
Du RoseN. (2017). Marginalised drug-using women’s pleasure and agency. The Social History of Alcohol and Drugs, 31(1), 42–64.
15.
ElliottL.GolubA.BennettA.GuarinoH. (2015). PTSD and cannabis-related coping among recent veterans in New York city. Contemporary Drug Problems, 42(1), 60–76. https://doi.org/10.1177/0091450915570309
16.
ElmsL.ShannonS.HughesS.LewisN. (2019). Cannabidiol in the treatment of post-traumatic stress disorder: A case series. The Journal of Alternative and Complementary Medicine, 25(4), 392–397. https://doi.org/10.1089/acm.2018.0437
17.
FraserG. A. (2009). The use of a synthetic cannabinoid in the management of treatment‐resistant nightmares in posttraumatic stress disorder (PTSD). Neuroscience and Therapeutics, 15(1), 84–88. https://doi.org/10.1111/j.1755-5949.2008.00071.x
18.
GradusJ. L. (2017). Prevalence and prognosis of stress disorders: A review of the epidemiologic literature. Clinical Epidemiology, 9, 251–260. https://doi.org/10.2147/CLEP.S106250
19.
HillM. N.CampolongoP.YehudaR.PatelS. (2018). Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology, 43(1), 80–102. https://doi.org/10.1038/npp.2017.162
20.
HoskinsM.PearceJ.BethellA.DankovaL.BarbuiC.TolW. A.BissonJ. I. (2015). Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. The British Journal of Psychiatry, 206(2), 93–100. https://doi.org/10.1192/bjp.bp.114.148551
21.
LaFranceE. M.GlodoskyN. C.Bonn-MillerM.CuttlerC. (2020). Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. Journal of Affective Disorders, 274, 298–304. https://doi.org/10.1016/j.jad.2020.05.132
22.
LoflinM.EarleywineM.Bonn-MillerM. (2017). Medicinal versus recreational cannabis use: Patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD. Addictive Behaviors, 68, 18–23. https://doi.org/10.1016/j.addbeh.2017.01.008
23.
LucasC. J.GalettisP.SchneiderJ. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology, 84(11), 2477–2482. https://doi.org/10.1111/bcp.13710
24.
MacleodR.ShepherdL.ThompsonA. R. (2016). Posttraumatic stress symptomatology and appearance distress following burn injury: An interpretative phenomenological analysis.Health Psychology, 35(11), 1197–1204. https://doi.org/10.1037/hea0000391
25.
MathesonJ.BourgaultZ.Le FollB. (2022). Sex differences in the neuropsychiatric effects and pharmacokinetics of cannabidiol: A scoping review. Biomolecules, 12(10), 1462. https://doi.org/10.3390/biom12101462
26.
Meshberg-CohenS.KachadourianL.BlackA. C.RosenM. I. (2017). Relationship between substance use and attitudes towards seeking professional psychological help among veterans filing PTSD claims. Addictive Behaviors, 74, 9–12. https://doi.org/10.1016/j.addbeh.2017.05.024
27.
MetcalfO.VarkerT.ForbesD.PhelpsA.DellL.DibattistaA.RalphN.O’ DonnellM. (2016). Efficacy of fifteen emerging interventions for the treatment of posttraumatic stress disorder: A systematic review. Journal of Traumatic Stress, 29(1), 88–92. https://doi.org/10.1002/jts.22070
28.
Ministry of Health (2021). Licenses for cannabis use.
29.
Mizrachi Zer-AvivT.SegevA.AkiravI. (2016). Cannabinoids and Post-traumatic stress disorder: Clinical and preclinical evidence for treatment and prevention. Behavioural Pharmacology, 27(7), 561–569. https://doi.org/10.1097/FBP.0000000000000253
30.
MorenaM.NastaseA. S.SantoriA.CravattB. F.ShanskyR. M.HillM. N. (2021). Sex‐dependent effects of endocannabinoid modulation of conditioned fear extinction in rats. British Journal of Pharmacology, 178(4), 983–996. https://doi.org/10.1111/bph.15341
31.
NajavitsL. M. (2015). The problem of dropout from “gold standard” PTSD therapies. F1000prime Reports, 7, 43–51. https://doi.org/10.12703/P7-43
32.
National Academies of Sciences, Engineering and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press.
33.
O’NeilM. E.NugentS. M.MorascoB. J.FreemanM.LowA.KondoK.ZakherB.ElvenC.Motu’ApuakaM.PaynterR.KansagaraD. (2017). Benefits and harms of plant-based cannabis for posttraumatic stress disorder: A systematic review. Annals of Internal Medicine, 167(5), 332.
34.
OrsoliniL.ChiappiniS.VolpeU.De BerardisD.LatiniR.PapantiG. D.CorkeryJ. M. (2019). Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): A systematic review. Medicina, 55, 525–537. https://doi.org/10.3390/medicina55090525
35.
RauchS. A.EftekhariA.RuzekJ. I. (2012). Review of exposure therapy: A gold standard for PTSD treatment. Journal of Rehabilitation Research Devlopment, 49(5), 679–687.
36.
SchottenbauerM. A.GlassC. R.ArnkoffD. B.TendickV.GrayS. H. (2008). Nonresponse and dropout rates in outcome studies on PTSD: Review and methodological considerations. Psychiatry, 71, 134–168. https://doi.org/10.1521/psyc.2008.71.2.134
SteenkampM. M.BlessingE. M.Galatzer‐LevyI. R.HollahanL. C.AndersonW. T. (2017). Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. Depression and Anxiety, 34(3), 207–216. https://doi.org/10.1002/da.22596
39.
ThomasD.SteinD. J. (2016). Novel pharmacological treatment strategies for posttraumatic stress disorder. Expert Review of Clinical Pharmacology, 10(2), 167–217. https://doi.org/10.1080/17512433.2017.1260001
40.
Tirado-MuñozJ.Lopez-RodriguezA. B.FonsecaF.FarréM.TorrensM.ViverosM. P. (2020). Effects of cannabis exposure in the prenatal and adolescent periods: Preclinical and clinical studies in both sexes. Frontiers in Neuroendocrinology, 57, 100841–100863. https://doi.org/10.1016/j.yfrne.2020.100841
41.
WilkinsonS.RadhakrishnanR.D'SouzaD. C. (2016). A systematic review of the evidence for medical marijuana in psychiatric indications. Journal of Clinical Psychiatry, 77(8), 1050- 1064. https://doi.org/10.4088/JCP.15r10036
42.
YehudaR.BiererL. M. (2009). The relevance of epigenetics to PTSD: Implications for the DSM‐V. Journal of Traumatic Stress, 22(5), 427–434. https://doi.org/10.1002/jts.20448
